Published: June 29, 2020 18:27:24 | Updated: July 01, 2020 20:34:17
Gilead Sciences Inc said on Monday it has priced its COVID-19 treatment candidate remdesivir at $390 per vial in the United States and other developed countries.
Based on current treatment patterns, the vast majority of patients are expected to receive a five-day treatment course using six vials of remdesivir, which equates to $2,340 per patient, reports Reuters citing the company.
Moderna to make milestone payments to US for Covid-19 vaccine
Bird flu situation 'worrying', WHO working with Cambodia
A woman dies every two minutes due to pregnancy or childbirth: UN report
Oral dose of azithromycin at normal birth can reduce 33pc maternal sepsis and deaths: Study
Can topical treatment alone fix acne scars?
Vitamin A-plus campaign for 22.0 million children held
Why the success of making an artificial heart remains elusive?
No specific research on zinc level in rice
© 2024 - All Rights with The Financial Express
